Cortellis
Powering Life Sciences Innovation
Clarivate Analytics Cortellis Deal of the Year
Clarivate Analytics is pleased to announce the return of our esteemed Cortellis Deals of the Year!
Partnerships are the lifeblood of the biopharma industry. But what makes a good deal? Our experts at Cortellis have sifted through the licensing partnerships and mergers & acquisitions of 2017 and have nominated five deals in each category for the Clarivate Analytics Cortellis Deals of the Year. The awards will be determined by a public vote. Winners will be announced in mid-February 2018.
Review the deals and vote now!
2017 Cortellis Deal of the Year Nominees: Licensing Partnerships
| Licensee | Licensor | Total Size ($M) | Upfront + Equity ($M) | Overview | Area; Stage | As Reported in BioWorld |
|---|---|---|---|---|---|---|
| AstraZeneca | Pieris | $2,145 | $45 | AstraZeneca to develop and commercialize inhaled drugs, including PRS-060, using Pieris's Anticalin platform for respiratory diseases. | Respiratory; Discovery | Inhaling anticalins: Pieris, Astrazeneca ink $2.1B pact for respiratory disease |
| Celgene | BeiGene | $1,393 | $263 + $150 | Celgene and BeiGene to develop and commercialize BGB-A317 against solid tumors worldwide except Asia. | Cancer; Launched | Celgene snags Beigene PD-1 inhibitor for $413M up front and up to $980M in milestones |
| Amgen | CytomyX | $1,668 | $40 + $20 | Amgen and CytomX to codevelop T-cell engaging bispecific antibodies against EGFR and certain immuno-oncology targets worldwide. | Cancer; Discovery | Amgen taps Cytomyx Therapeutics in potential $1.47B bispecific deal |
| Eli Lilly | CureVac | $1,803 | $50 + $53 | Lilly to use CureVac's RNActive technology for development and commercialization of up to five cancer vaccine products worldwide. | Cancer; Discovery | Curevac’s mRNA vaccine draws Lilly in potential $1.8B deal |
| AbbVie | Alector | $225 | $205 + $20 | AbbVie to develop and commercialize Alector's immune therapies against AD and other neurodegenerative disorders worldwide. | Neurology; Discovery | Full-court press by Alector |
2017 Deal of the Year Nominees: Mergers & Acquisitions
| Buyer | Seller | Financials (USD) | Ownership | Overview | Area; Stage | As Reported in BioWorld |
|---|---|---|---|---|---|---|
| Johnson & Johnson | Actelion | $30B | Public | J&J gains worldwide rights to ponesimod and cadazolid. Actelion spins out research and early-stage assets into new company. | Diversified; Launched | J&J, Actelion finalize $30B takeover in one of biopharma’s largest M&A deals |
| Bioverativ | True North | $400M upfront +$425M in milestones | Private | Bioverativ acquires True North, a clinical stage company focused on candidates for complement mediated diseases. | Diversified; Phase 1 | Bioverativ paying up to $825M for rare blood disorder specialist True North |
| Bristol- Myers Squibb | IFM Therapeutics | $300M upfront + $1.01B in milestones for each of two programs | Private | Bristol-Myers Squibb’s acquisition of IFM Therapeutics includes IFM's preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs. | Cancer; Discovery | BMS looks to ‘marry’ adaptive, innate immunity with $2.32B+ IFM buy |
| Gilead | Kite Pharma | $11.9B | Public | Gilead acquires Kite, developer of cell therapies that express either a chimeric antigen receptor (CAR) or engineered T cell receptor (TCR), depending on cancer type. | Cancer; Pre-registration | Gilead Sciences flies an $11.9B Kite high into cell therapy, immuno-oncology |
| Merck | Rigontec | $552.30M | Private | Merck acquires Rigontec, University of Bonn spinout, focused on developing retinoic acid-inducible gene I (RIG-I) targeting therapies for various tumors. | Cancer; Phase 1 | Merck snags Rigontec for $137M up front, $416M in milestones |
Click here to cast your vote!
Our experts have provided you with deal details from Cortellis Competitive Intelligence, the comprehensive tool that provides accurate and timely global information on drugs, companies, patents, clinical trials, biopharma deals and much more; and from Cortellis Deals Intelligence (CDI), the unique database that allows customers to assess comparable deals in depth, including contracts filed with the U.S. SEC and versions showing previously redacted dollar amounts. CDI includes more than 85,000 deals. Also included are links to the coverage of each deal from BioWorld, the daily biopharma news service from Clarivate Analytics.
Join us for Clarivate Analytics’ Annual Deals and Portfolio Review taking place during JPM.
What were the Dealmaking trends of 2017? Join Clarivate Analytics, in San Francisco during the 36th Annual JP Morgan Healthcare Conference, to hear about the exciting Dealmaking from 2017.
January 8 & 9, 2018, Hotel Zetta
Get ahead with daily insights on the latest news from the biopharma industry.
BioWorld delivers actionable intelligence on the most innovative drug development science that drives the business, which funds the means to heal disease. With writers and editors stationed around the globe, BioWorld reports the breaking news.
@Clarivate
Clarivate Analytics